{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-22-007211","form_type":"8-K","ticker":"AGEN","cik":"0001098972","company_name":"AGENUS INC","filed_at":"2022-11-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:49.601041+00:00","generated_at":"2026-06-22T02:49:44.259710+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Agenus reports Q3 net loss $56.7M, cash $218.2M; botensilimab Phase 2 trials initiated","bullets":["Q3 2022 net loss $56.7M ($0.19/sh) vs prior-year net income; revenue $22.8M, down from $253M largely due to prior milestone.","Cash and investments $218.2M vs $306.9M at Dec 2021; cash used in operations $32.2M in Q3.","Initiated Phase 2 ACTIVATE trials of botensilimab in advanced MSS colorectal cancer and melanoma.","Expanded leadership: Patricia Carlos named Chief Regulatory, Quality & Safety Officer; Todd Yancey as Senior Clinical Advisor.","Partner programs advancing: BMS, Merck, Incyte ongoing Phase 2/1 trials for discovered assets."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-22-007211","json":"https://secwatch.observer/filing/0001171843-22-007211.json","markdown":"https://secwatch.observer/filing/0001171843-22-007211.md","text":"https://secwatch.observer/filing/0001171843-22-007211.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1098972/000117184322007211/0001171843-22-007211-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1098972/000117184322007211/f8k_110722.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T02:49:44.259710+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"ca7ad9831568fb9d382a7e71bf4068ede4c1c617","claim":"AGENUS INC reported the third quarter of 2022 results: revenue $22.8 million, net income $56.7 million, EPS $0.19 per share.","evidence_excerpt":"We recognized revenue of $22.8 million and incurred a net loss of $56.7 million, or $0.19 per share, for the third quarter ended September 30, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1098972/000117184322007211/0001171843-22-007211-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter of 2022"},{"label":"Revenue","value":"$22.8 million"},{"label":"Net income","value":"$56.7 million"},{"label":"EPS","value":"$0.19 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}